Comparative Pharmacology
Head-to-head clinical analysis: INVAGESIC versus PERCODAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVAGESIC versus PERCODAN.
INVAGESIC vs PERCODAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INVAGESIC is a combination of pregabalin, an alpha2-delta ligand that inhibits presynaptic calcium channels to reduce excitatory neurotransmitter release, and meloxicam, a COX-2 selective NSAID that decreases prostaglandin synthesis via cyclooxygenase inhibition.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia. Oxycodone acts on the central nervous system (CNS) to produce analgesia. Aspirin inhibits cyclooxygenase, leading to decreased prostaglandin synthesis, which reduces pain and inflammation.
Adults: 1-2 tablets (325 mg acetaminophen/5 mg hydrocodone) orally every 4-6 hours as needed for pain, not to exceed 12 tablets per day.
1-2 tablets orally every 4-6 hours as needed for pain. Each tablet contains oxycodone 4.5 mg and aspirin 325 mg.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; prolonged to 8-12 hours in elderly or mild renal impairment
Oxycodone: 3-5 hours, prolonged in elderly, hepatic/renal impairment. Aspirin: 2-3 hours at low doses; 15-30 hours at anti-inflammatory doses due to saturable metabolism.
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites
Oxycodone: primarily renal (65-87% as parent and metabolites, mostly noroxycodone and oxymorphone conjugates); ~10% fecal. Aspirin: renal (75-90% as salicylates and metabolites, dose-dependent).
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination